A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase II/III Clinical Trial to Compare the Safety and Efficacy of NABOTA Versus BOTOX in Treatment of Essential Blepharospasm
Latest Information Update: 27 Jun 2019
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Blepharospasm
- Focus Therapeutic Use
- Sponsors Daewoong Pharmaceutical
- 25 Jun 2019 Status changed from recruiting to completed.
- 04 Nov 2016 New trial record